Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic ColorectalCancer: The Open-Label, Randomized, Phase III TAILOR Trial Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectalcancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX) has
Bevacizumab (Mvasi) - Metastatic ColorectalCancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product
–170. 8. Novelli M, Rossi S, Rodriguez-Justo M et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57: 259–270. 9. Gasparotto D, Rossi S, Polano M et al. Quadruple-negative GIST is a sen- tinel for unrecognized neuro?bromatosis type 1 syndrome. Clin Cancer Res 2017; 23: 273–282. 10. Brierley JD, Gospodarowicz MK, Wittekind C. (eds). TNM Classi?cation of MalignantTumours, 8th edn. Oxford: John Wiley & Sons, Inc. 2016. 11 (...) imatinib for high- risk GI stromal tumor: analysis of a randomized trial. J Clin Oncol 2016; 34: 244–250. 17. Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesy- late after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097–1104. 18. Gronchi A, Judson I, Nishida T et al. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue
subtype of squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, we randomly assigned patients to undergo minimally invasive surgery or open surgery. The primary outcome was the rate of disease-free survival at 4.5 years, with noninferiority claimed if the lower boundary of the two-sided 95% confidence interval of the between-group difference (minimally invasive surgery minus open surgery) was greater than -7.2 percentage points (i.e., closer to zero).A total of 319 patients were (...) , body-mass index, stage of disease, lymphovascular invasion, and lymph-node involvement; minimally invasive surgery was also associated with a lower rate of overall survival (3-year rate, 93.8% vs. 99.0%; hazard ratio for death from any cause, 6.00; 95% CI, 1.77 to 20.30).In this trial, minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer. (Funded
Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III coloncancer Adjuvant Chemotherapy Trial of TS-1 for ColonCancer (ACTS-CC), a randomised phase III trial, demonstrated that adjuvant therapy with S-1 for stage III coloncancer was non-inferior in 3-year disease-free survival (DFS) to that of tegafur-uracil plus leucovorin (UFT/LV). We updated DFS (...) and overall survival (OS) and performed T x N subset analysis.A total of 1518 patients with curatively resected stage III coloncancer were randomly assigned to receive S-1 (80-120 mg/day on days 1-28 every 42 days, four courses) or UFT/LV (UFT: 300-600 mg/day and LV: 75 mg/day on days 1-28 every 35 days, five courses).The 5-year DFS rates of the S-1 and UFT/LV group were 70.2 % and 66.9 %, respectively (HR 0.88; 95% CI 0.74 to 1.06; p=0.177), and non-inferiority of DFS was reconfirmed with a median
Can nut consumption improve coloncancer survival? 30363796 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Can nut consumption improve coloncancer survival? 73 10.21037/tgh.2018.09.14 Aune Dagfinn D Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK. Department of Nutrition, Bjørknes University College, Oslo, Norway. Department of Endocrinology, Morbid Obesity and Preventive Medicine
Surgical treatment of gastrointestinal stromal tumors of the duodenum: a literature review Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumours in the digestive tract. The duodenal GIST (dGIST) is the rarest subtype, representing only 4-5% of all GIST, but up to 21% of the resected ones. The diagnostic and therapeutic management of dGIST may be difficult due to the rarity of this tumor, its anatomical location, and the clinical behavior that often mimic a variety (...) patients with dGIST: twenty-seven patients were treated with pancreatoduodenectomy and ninety-six with only local resection (segmental/wedge resections); in four hundred twenty-six patients it is not possible identify the type of treatment performed (pancreatoduodenectomy or segmental/wedge resections).dGISTs are a very rare subset of GISTs. They may be asymptomatic or may involve symptoms of upper GI bleeding and abdominal pain at presentation. Because of the misleading clinical presentation
Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on ColorectalCancer Detection: A Community-Based Cohort Study. The fecal immunochemical test (FIT) is commonly used for colorectalcancer (CRC) screening. Despite demographic variations in stool hemoglobin concentrations, few data exist regarding optimal positivity thresholds by age and sex.To identify programmatic (multitest) FIT performance characteristics and optimal FIT quantitative hemoglobin positivity (...) thresholds in a large, population-based, screening program.Retrospective cohort study.Kaiser Permanente Northern and Southern California.Adults aged 50 to 75 years who were eligible for screening and had baseline quantitative FIT results (2013 to 2014) and 2 years of follow-up. Nearly two thirds (411 241) had FIT screening in the previous 2 years.FIT programmatic sensitivity for CRC and number of positive test results per cancer case detected, overall and by age and sex.Of 640 859 persons who completed
Recent advances in colorectalcancer screening 30276360 2018 11 14 2589-0514 4 3 2018 Sep Chronic diseases and translational medicine Chronic Dis Transl Med Recent advances in colorectalcancer screening. 139-147 10.1016/j.cdtm.2018.08.004 Li Dan D Department of Gastroenterology, Kaiser Permanente Medical Center, Santa Clara, CA 95051, USA. Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA. eng Editorial 2018 09 17 China Chronic Dis Transl Med 101679934 2095 (...) -882X Colonoscopy Colorectalcancer Screening 2018 06 26 2018 10 3 6 0 2018 10 3 6 0 2018 10 3 6 1 epublish 30276360 10.1016/j.cdtm.2018.08.004 S2095-882X(18)30060-4 PMC6160607 Lancet. 2013 Apr 6;381(9873):1185-93 23414648 Am J Surg Pathol. 2004 Nov;28(11):1452-9 15489648 Gastroenterology. 2016 Nov;151(5):870-878.e3 27443823 CA Cancer J Clin. 2017 May 6;67(3):177-193 28248415 Gastroenterology. 2015 Sep;149(3):777-82; quiz e16-7 26226577 Am J Gastroenterol. 2012 Sep;107(9):1315-29; quiz 1314, 1330
percentage points; 95% CI, 0.1%-6.8%) and any colorectalcancer screening (18.3% vs 14.5%; difference, 3.8 percentage points; 95% CI, 0.6%-7.0%). We observed large variation across health centers in effectiveness (FIT completion differences range, -7.4 percentage points to 17.6 percentage points) and implementation (proportion who were mailed a FIT range, 6.5% to 68.2%). The number needed to mail to achieve a completed FIT was 4.8 overall, and 4.0 in clinics that mailed a FIT reminder.An EHR-embedded (...) Effectiveness of a Mailed ColorectalCancer Screening Outreach Program in Community Health Clinics: The STOP CRC Cluster Randomized Clinical Trial Approximately 24 million US individuals receive care at federally qualified health centers, which historically have low rates of colorectalcancer screening. The US Preventive Services Task Force recommends routine colorectalcancer screening for individuals aged 50 to 75 years.To determine the effectiveness of an electronic health record (EHR
New Development of Biomarkers for GastrointestinalCancers: From Neoplastic Cells to Tumor Microenvironment Biomarkers refer to a plethora of biological characteristics that can be quantified to facilitate cancer diagnosis, forecast the prognosis of disease, and predict a response to treatment. The identification of objective biomarkers is among the most crucial steps in the realization of individualized cancer care. Several tumor biomarkers for gastrointestinalmalignancies have been applied (...) in the clinical setting to help differentiate between cancer and other conditions, facilitate patient selection for targeted therapies, and to monitor treatment response and recurrence. With the coming of the immunotherapy age, the need for a new development of biomarkers that are indicative of the immune response to tumors are unprecedentedly urgent. Biomarkers from the tumor microenvironment, tumor genome, and signatures from liquid biopsies have been explored, but the majority have shown a limited
Home parenteral nutrition for people with inoperable malignantbowel obstruction. People with advanced ovarian or gastrointestinalcancer may develop malignantbowel obstruction (MBO). They are able to tolerate limited, if any, oral or enteral (via a tube directly into the gut) nutrition. Parenteral nutrition (PN) is the provision of macronutrients, micronutrients, electrolytes and fluid infused as an intravenous solution and provides a method for these people to receive nutrients
Current treatment strategies in pediatric gastrointestinal stromal cell tumorGastrointestinal stromal tumors (GIST) are exceedingly rare tumors in the pediatric population. As a result, many clinicians either may never see this diagnosis or will encounter it only a few times throughout their careers. Additionally, the more we discover about this disease, it becomes evident that it represents a distinct clinical entity from adult GIST. Many of the treatments and strategies used to combat (...) the adult tumor are either ineffective or may be harmful to the pediatric population with this disease. The unique tumor biology found in pediatric GIST necessitates unique approaches and treatment strategies in order to achieve the best clinical outcome. This review aims to discuss the most recent data available on the different therapeutic modalities utilized in cases of Pediatric GIST.
Pharmaconutrition administration on outcomes of elective oncological surgery for gastrointestinalmalignancies: is timing everything?â€”a review of published meta-analyses until the end of 2016 The last 25 years have seen an increasing number of publications attesting the benefits of pharmaconutrition in the management of patients undergoing elective oncological gastrointestinal surgery. A number of randomized controlled trials and meta-analyses suggest the use of pharmaconutrition (...) in this group of patients produces superior outcomes to standard nutritional formulations in terms of postoperative infective complications, anastomotic breakdown and length of hospital stay. The use of pharmaconutrition products, therefore, has gained increasing acceptance for use in elective gastrointestinal oncological surgical populations and been incorporated into practice guidelines. However, there remains doubts as to the robustness of such data supporting these recommendation. This is because
Macrophage repolarisation therapy in colorectalcancer 30116595 2018 08 17 2059-7029 3 5 2018 ESMO open ESMO Open Macrophage repolarisation therapy in colorectalcancer. e000426 10.1136/esmoopen-2018-000426 Halama Niels N Department of Medical Oncology and Internal Medicine VI, National Center for TumorDiseases, UniversitatsKlinikum Heidelberg, Heidelberg, Germany. eng Journal Article 2018 08 03 England ESMO Open 101690685 2059-7029 Podcast Competing interests: None declared. 2018 8 18 6 0
for Disease Control and Prevention (CDC's) Screen for Life materials. Some participants also will be asked to read a personal narrative about coloncancer screening . This study will determine whether participant's perceptions about 2015 16. Colon Capsule to Screen for ColorectalNeoplasia in Subjects with a Family History of ColorectalCancer . BACKGROUND AND AIMS: Colon capsule endoscopy (CCE) has been recognized as an alternative for colorectalcancer (CRC) screening in average risk subjects (...) administration is a key factor in the tolerability and efficacy of colon preparation in colorectalcancer screening ]. 236-42 10.1016/j.gastrohep.2012.01.012 The quality and tolerability of antegrade (...) gut lavage bowel preparation are key elements in the success of population-based colorectalcancer screening . To evaluate cleansing quality and tolerability according to the timing of polyethylene glycol administration in persons undergoing colorectalcancer screening . Participants in colorectalcancer
cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages. OBJECTIVE: To assess the net balance of benefits and harms from routine aspirin use across clinically relevant age, sex 2016 7. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectalcancer : a systematic review and economi The clinical effectiveness (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for colorectalcancer The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many
Incidence of faecal occult blood test interval cancers in population-based colorectalcancer screening: a systematic review and meta-analysis Faecal immunochemical tests (FITs) are replacing guaiac faecal occult blood tests (gFOBTs) for colorectalcancer (CRC) screening. Incidence of interval colorectalcancer (iCRC) following a negative stool test result is not yet known. We aimed to compare incidence of iCRC following a negative FIT or gFOBT.We searched Ovid Medline, Embase, Cochrane Library